VEGFR2 but not VEGFR3 governs integrity and remodeling of thyroid angiofollicular unit in normal state and during goitrogenesis by Jeon Yeob Jang et al.
Research Article
VEGFR2 but not VEGFR3 governs integrity and
remodeling of thyroid angiofollicular unit in normal
state and during goitrogenesis
Jeon Yeob Jang1,2,3,†, Sung Yong Choi2,†, Intae Park1,2, Do Young Park1,2, Kibaek Choe4,
Pilhan Kim4, Young Keum Kim5, Byung-Joo Lee3, Masanori Hirashima6, Yoshiaki Kubota7,
Jeong-Won Park8, Sheue-Yann Cheng8, Andras Nagy9, Young Joo Park10, Kari Alitalo11,
Minho Shong12,* & Gou Young Koh1,4,**
Abstract
Thyroid gland vasculature has a distinguishable characteristic of
endothelial fenestrae, a critical component for proper molecular
transport. However, the signaling pathway that critically governs
the maintenance of thyroid vascular integrity, including endothe-
lial fenestrae, is poorly understood. Here, we found profound and
distinct expression of follicular epithelial VEGF-A and vascular
VEGFR2 that were precisely regulated by circulating thyrotropin,
while there were no meaningful expression of angiopoietin–Tie2
system in the thyroid gland. Our genetic depletion experiments
revealed that VEGFR2, but not VEGFR3, is indispensable for mainte-
nance of thyroid vascular integrity. Notably, blockade of VEGF-A or
VEGFR2 not only abrogated vascular remodeling but also inhibited
follicular hypertrophy, which led to the reduction of thyroid
weights during goitrogenesis. Importantly, VEGFR2 blockade alone
was sufficient to cause a reduction of endothelial fenestrae with
decreases in thyrotropin-responsive genes in goitrogen-fed
thyroids. Collectively, these findings establish follicular VEGF-A–
vascular VEGFR2 axis as a main regulator for thyrotropin-
dependent thyroid angiofollicular remodeling and goitrogenesis.
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Introduction
Thyroid gland is the largest endocrine organ in our body and is
composed of epithelial follicles that are uniformly interfaced with
fenestrated capillaries to make up “angiofollicular units” for
proper secretion of thyroid hormones (Colin et al, 2013). Endo-
crine function of thyroid gland is primarily regulated by thyro-
tropin (thyroid-stimulating hormone, TSH) that is secreted from
pituitary thyrotropes (Chiamolera & Wondisford, 2009; Brent,
2012). Circulating thyrotropin specifically activates its receptor
on basolateral membrane of thyroid follicular epithelial cells
(thyrocytes) (Colin et al, 2013). Conditions of hyper-activation of
thyrotropin receptor such as Graves’ disease display follicular
hyperplasia and a parallel increase in capillary density in thyroid
gland (Davies et al, 2005). Thus, alteration of thyrotropin
receptor activation may modulate not only the structure and
endocrine function of thyroid follicular cells but also their
surrounding capillaries via regulating their secretion of angio-
genic factors (Imada et al, 1986a,b; Davies et al, 2005; Colin
et al, 2013).
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Endothelial cells (ECs) perform and maintain diverse and
heterogeneous functions in different organs and tissues such as
bone, retina, liver, uterus, and Schlemm’s canal in eye (Aird,
2007a,b; Kim et al, 2013; Aspelund et al, 2014; Hu et al, 2014;
Kusumbe et al, 2014; Park et al, 2014). In case of thyroid
glands, each thyroid follicle is surrounded by a rich capillary
network which provides substrates for hormone synthesis and
transports the released hormones (Colin et al, 2013). The thyroid
capillaries have a distinguishable characteristic of endothelial
fenestrae, transcellular pores that are 60–80 nm in diameter
spanned by fenestral diaphragms, which is a critical component
in the vasculatures of endocrine organs for proper transport of
low-molecular weight hydrophilic molecules (Esser et al, 1998;
Risau, 1998; Kamba et al, 2006). The propinquity of the fenes-
trated endothelium to thyroid follicular epithelium suggests that
these two cell types interact with each other to develop and
maintain the fenestrae (Risau, 1998). However, how the fenes-
trae in the endothelium of thyroid are maintained and regulated
needs to be finely defined.
Maintenance of thyroid vasculature integrity is known to be
majorly regulated by two key vascular ligands–receptor systems:
vascular endothelial growth factors (VEGFs) and their receptors
(VEGFRs), and angiopoietins (Angs) and the Tie2 receptor
(Carmeliet, 2003; Augustin et al, 2009; Lohela et al, 2009; Chung &
Ferrara, 2011). Earlier studies indicated that VEGF-A produced by
thyroid follicle cells in response to stimulators of TSHR in thyroid
glands is the key factor for maintenances of vascular density and
endothelial fenestrae in the thyroid glands (Sato et al, 1995;
Viglietto et al, 1997; Ramsden, 2000; Kamba et al, 2006; Colin et al,
2013). Moreover, in certain conditions such as thyroid goiter, in
which TSHR is hyper-activated, high expression of VEGF-A has been
noted (Nagura et al, 2001). Furthermore, blockades of VEGF-A or
Angs have been reported to alleviate experimental goitrogenesis
(Ramsden et al, 2005). However, the mechanical insights behind
how such beneficial effects occur are still lacking. Moreover, expres-
sion and roles of vascular ligands–receptors, VEGFRs and Tie2, in
the thyroid capillaries need to be better defined to identify a reason-
able therapeutic avenue for thyroid goiter.
In this study, we determined the expression patterns of the two
vascular systems, evaluated the patterns of follicular and vascular
remodeling and their key regulators under different TSH levels, and
investigated the molecular pathway responsible for mediating
TSHR-associated follicular remodeling and goitrogenesis.
Results
Profound and distinct expression of VEGF-A, VEGFR2, and
VEGFR3, but no Ang1, Ang2, and Tie2, in thyroid glands
To gain insight into the role of vascular ligand–receptor system in
thyroid glands, we first examined their relative expression in thyroid
glands and compared those levels with other organs. Quantitative
real-time PCR analyses revealed that VEGF-A mRNA expression was
~sixfold higher and PDGF-B mRNA expression was ~twofold higher,
but the mRNA expression of VEGF-C, VEGF-D, angiopoietin-1
(Ang1), angiopoietin-2 (Ang2), and PDGF-A was either slightly
higher, lower, or similar in the thyroid glands compared with other
adjacent organs—esophagus and trachea (Fig 1A). Supporting these
findings, semi-quantitative RT–PCR analyses revealed that the three
major isoforms of VEGF-A—VEGF120, VEGF164, and VEGF188—were
highly expressed in the thyroid gland compared with other organs
including lung, liver, kidney, and adrenal glands (Fig 1B). More-
over, VEGF164 was continuously secreted by the tissue explants of
the thyroid glands (Fig 1C). Consistent with these findings, reporter
mice analyses revealed that VEGF-A was highly expressed in the
thyroid glands, while VEGF-C was barely detectable (Fig 1D and
Appendix Fig S1A). High-magnification images showed that VEGF-A
expression was confined to within the follicular cells, not to the
surrounding ECs (Fig 1D). In fact, compared with the adjacent
organs, the thyroid gland had dense but well-arranged vasculatures
that surround each thyroid follicle (Fig 1E and F). ECs of the vascu-
latures highly expressed VEGFR2 and moderately expressed
VEGFR3 (Fig 1G), but rarely expressed Tie2 (Fig 1H), which is in
contrast to a previous report (Ramsden et al, 2005). Of note, our
analysis using reporter mice indicated that both Ang1 and Ang2
were not detectable in thyroid gland, while Ang1 was detected in
megakaryocytes in bone marrow and Ang2 was detected in the tip
ECs of growing retinal vessels (Fig 1H and Appendix Fig S1B and
C). These data clearly indicate that Ang–Tie2 system is not the
major pathway regulating thyroid angiofollicular unit. Collectively,
these data suggest that the capability of transcellular transport in
▸Figure 1. Robust and distinct expression of VEGF-A and VEGFR2 in the thyroid gland.A Comparisons of mRNA levels of genes that regulate angiogenesis in thyroid glands and adjacent organs including trachea and esophagus. Data are presented as
relative folds to the levels of trachea after normalization with b-actin. Each group, n = 3.
B Semi-quantitative RT–PCR showing mRNA expression of VEGF-A. Each line indicates gene transcripts of VEGF-A120, VEGF-A164, and VEGF-A188.
C Concentration of VEGF-A in supernatants at the indicated times after explant culture of the thyroid glands. Each group, n = 5.
D Images showing X-gal-stained VEGF-A in the thyroid glands (Tg) of VEGF-A+/LacZ mouse. In right lower panel, the tissues were immunostained with anti-CD31
antibody after X-gal staining.
E Images showing CD31+ BVs of a thyroid gland (Tg) and adjacent organs including a trachea (Tr) and an esophagus (Es). Indicated region (white dotted square) is
viewed under high magnification at the right panel. DAPI staining for nuclei.
F Image showing three-dimensional distribution of BVs in thyroid follicle.
G Images showing VEGFR2+VEGFR3+ thyroid gland vasculature. Right panel, X-gal staining for VEGFR2 in the thyroid glands of VEGFR2+/LacZ mouse.
H Images showing barely detectable GFP signal from the thyroid glands of Tie2-GFP, Ang1-GFP, and Ang2-GFP reporter mice. Right panel, immunofluorescence staining
for Ang2.
Data information: All scale bars, 50 lm except scale bars in (E), 200 lm. Kruskal–Wallis test followed by Tukey’s multiple comparison test was used in (A and C). Error
bars represent mean  s.d. in (A and C).
Source data are available online for this figure.
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thyroid glands is mainly regulated through a paracrine interaction
between VEGF-A, which is continuously secreted from follicular
cells, and VEGFR2- or VEGFR3-expressing ECs.
Dynamic changes in angiofollicular unit and number of
endothelial fenestrae in thyroid glands by circulating TSH
To get an insight about how the dynamic changes in thyroid capil-
laries occur, we determined the influence of TSHR signaling on the
thyroid gland vasculature by adapting an indirect but clinically rele-
vant mouse model (Franco et al, 2011) by administering levo-
thyroxine (T4, ~0.6 mg/kg/day) or 6-propyl-2-thiouracil (PTU,
~0.72 g/kg/day) in drinking water for 3 weeks to modulate circulat-
ing TSH level. Compared with control (8.5  8.1 ng/ml), T4
reduced serum TSH level (2.7  1.4 ng/ml), while PTU markedly
increased serum TSH level (187.6  138.1 ng/ml) (Appendix Fig
S2). Accordingly, shapes of follicular architectures were markedly
changed by the altered serum TSH levels by administrations of T4
and PTU (Fig 2A). Compared with control, T4 reduced the height of
follicular cells, vascular density, and vascular diameter in thyroid
gland by 62, 31, and 20% (Fig 2A–F). In contrast, PTU increased
the height of follicular cells, vascular density, and vascular diameter
in thyroid gland by 94, 45, and 194% (Fig 2A–F). Of note, neither
T4 nor PTU induced any apparent changes in the vasculatures of
other major organs such as the submandibular gland (Fig 2E and
G). PH3+ proliferating ECs were often detected in the thyroid gland
treated with PTU, while PH3+ ECs were not or rarely detectable in
the thyroid glands treated with control or T4 (Fig 2H and I), indicat-
ing that the increased EC proliferation could be involved in the PTU-
induced increase in vascular density and enlargement. Moreover,
intravital imaging analyses with rhodamine-conjugated RBC
revealed that the PTU-induced enlarged vessels in the thyroid gland
had strikingly increased blood flow (Movies EV1–EV3). Then, to
determine whether the PTU-induced vascular remodeling is rever-
sible, we examined the vasculatures 3 weeks after withdrawal of
PTU administration. Intriguingly, the vascular remodeling and
changes of follicular structures were almost completely restored to
normal status (Appendix Fig S3A–F). Thus, not only thyroid follicles
but also thyroid vasculatures are dynamically and finely adapted in
response to TSH stimulation.
We next questioned whether the modulation of TSHR signaling
can alter the ultrastructure of the discontinuous, fenestrated
endothelium in thyroid glands. Compared with control, capillaries of
thyroids treated with T4 appeared to be much thicker and had
decreased number of endothelial fenestrae by 66%, whereas they
showed markedly increased number of caveolae by 267% (Fig 2J
and M). In contrast, PTU increased the number of endothelial fenes-
trae by 41% without any notable changes in fenestrae shape or cave-
olae number (Fig 2J and M). These ultrastructural changes were
specific to thyroid glands and were undetectable in any other endo-
crine glands including the adrenal glands. Nevertheless, regardless
of T4 or PTU, distributions and amounts of VE-cadherin, a key adhe-
rens junctional protein in EC, and NG2+ pericytes were relatively
well preserved for the vessel in thyroid glands (Fig 2K, L and N).
These data indicate that a high level of TSH could increase the capa-
bility of transcellular transport by promoting EC content and the
number of intact fenestrae on each EC, whereas a low level of TSH
decreases the capability of transcellular transport by reducing EC
content and the number of fenestrae on each EC in thyroid glands.
Circulating TSH finely regulates the expression of VEGF-A,
VEGFR2, and VEGFR3
Based on these findings, we further explored whether follicular
VEGF-A expression is regulated by circulating TSH level using
VEGF-A reporter mice (Miquerol et al, 2000). VEGF-A expression in
the follicular cells was markedly reduced by T4 while being
increased by PTU compared with control (Fig 3A). Quantitative
real-time PCR analyses showed that, compared with control, the
overall expression level of VEGF-A mRNA was decreased by 39% in
T4-fed thyroids while being increased by 73% in PTU-fed thyroids
(Fig 3B). Concomitantly, the overall concentration of VEGF-A
protein was also decreased by 41% in T4-fed thyroids but increased
by 181% in PTU-fed thyroids (Fig 3C), while the serum level of
VEGF-A was not significantly changed under different circulating
TSH levels (Fig 3D). Consistent with these findings, the mRNA level
of VEGF-A in a thyroid follicular cell line, FRTL-5, was dose-
dependently increased 3 hr after TSH supplementation to growth
medium (Fig 3E and F). The TSH-responsive increment of VEGF-A
expression (increased by 85% compared with control) was abro-
gated by adding LY294002, a PI3K inhibitor, but neither the protein
kinase A inhibitor, KT5720, nor protein kinase C inhibitor, Go6976,
had any significant effect, indicating that PI3K pathway is presum-
ably responsible for the TSH-responsive increment of VEGF-A
expression in thyroid follicular cells (Fig 3G).
We also investigated the expression of VEGFR2 and VEGFR3
under different circulating TSH levels. VEGFR2 reporter mice (Ema
et al, 2006) analyses revealed that VEGFR2 expression in the perifol-
licular capillaries was reduced in T4-fed thyroids, whereas it was
moderately increased in PTU-fed thyroids compared with control
▸Figure 2. Dynamic follicular and vascular remodeling in thyroid glands by circulating TSH.A–D Images and comparisons of height of follicular cells and CD31+ vascular density.
E Intravital images after perfusion of FITC–dextran showing blood flow and vascular diameter of thyroid glands and submandibular glands (SMG).
F, G Comparisons of vascular diameter in thyroid and submandibular glands.
H, I Images and comparisons of PH3+ proliferating ECs in thyroid glands. Arrows indicate CD31+PH3+ proliferating ECs.
J Transmission electron micrographs showing the interface between ECs and follicular cells. Indicated region (white dotted square) is viewed under high
magnification at lower panel. Arrowheads indicate endothelial fenestrae, while arrows indicate endothelial caveolae. Scale bars, 0.5 lm.
K, L Images showing VE-cadherin distribution and NG2+ pericyte coverage on CD31+ BVs.
M Comparisons of the number of endothelial fenestrae and caveolae per 10 lm vessel perimeter.
N Comparisons of VE-cadherin expression (%) and NG2+ pericyte coverage on CD31+ BVs (%). Data are presented as percentage to the level of CD31 expression.
Data information: Each group, n = 5 in (B, D, F, G, I, and N). Each group, n = 3 in (M). Error bars represent mean  s.d. Kruskal–Wallis test followed by Tukey’s multiple
comparison test was used in (B, D, F, G, I, M, and N). ns, not significant. Scale bars, 50 lm.
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(Fig 3H). In agreement with this finding, the overall expression level
of VEGFR2 mRNA was decreased by 68% in T4-fed thyroids while
being increased by 118% in PTU-fed thyroids (Fig 3K). The overall
expression level of VEGFR3 mRNA showed similar results, being
decreased by 28% in T4-fed thyroids while being increased by
122% in PTU-fed thyroids (Fig 3K). Fluorescence image analyses
revealed that, under baseline conditions, the relative VEGFR expres-
sion was 71% for VEGFR2 and 30% for VEGFR3 on the CD31+ EC
(Fig 3I, J and L). However, T4 markedly decreased the relative
expression by 38% for VEGFR2 and 84% for VEGFR3, whereas PTU
increased the relative expression by 32% for VEGFR2 and by 164%
for VEGFR3 (Fig 3I, J and L). Thus, thyroid follicular VEGF-A and
endothelial VEGFR2 and VEGFR3 expressions are regulated propor-
tionally in response to TSH stimulation.
In addition, we further evaluated tissue hypoxic status within the
thyroid gland because VEGF-A expression has been known to be
induced in response to tissue hypoxia in many other systems
(Ferrara, 2004). However, tissue hypoxia, as quantified using
Hypoxyprobe-1 and GLUT1 expression (an alternative hypoxia
marker), was not meaningfully observed within the thyroid gland of
control, T4-treated, or PTU-treated mice, while they were highly
detected in the hypoxic regions of implanted glioblastoma (positive
control; Appendix Fig S4).
VEGFR2 but not VEGFR3 is indispensable for maintaining thyroid
vascular integrity during adulthood
We next questioned what the roles of constitutive expression of
VEGFR2 and VEGFR3 are for the maintenance of thyroid capillary
integrity at normal condition. To uncover the role of VEGFR2 in thyroid
capillaries, we generated VEGFR2iΔEC mice by mating the VEGFR2flox/flox
mouse (Hooper et al, 2009) with the VE-Cadherin-Cre-ERT2 mouse
(Fig 4A). As control mice, we used VE-Cadherin-Cre-ERT2 but flox/
flox-negative mice among the littermates for each experiment.
Repeated administrations of tamoxifen reduced expression of
VEGFR2 and VEGFR3 by 83 and 72% in the ECs of thyroid vascula-
tures of VEGFR2iΔEC mice compared with those of control mice
(Fig 4B–E). Vascular density and numbers of sprouting filopodia
and fenestrae were reduced by 43, 97, and 87%, while numbers of
apoptotic EC and caveolae were increased by 1,207 and 854% in
thyroid vasculatures of VEGFR2iΔEC mice compared with those of
control mice (Fig 4F–M). Electron micrograph (EM) images
showed that the cytoplasmic membrane of ECs of VEGFR2iΔEC mice
were thickened and nonfenestrated (Fig 4L), implying that the
capability of transcellular transport by the ECs of thyroid
vasculatures was markedly interrupted by the VEGFR2 depletion.
However, no apparent differences in gross features or vascular
density, network, and branching between the retinal vessels of
control and VEGFR2iΔEC mice were detected (Appendix Fig S5),
indicating that role of VEGFR2 in the vessels is organ-specific.
To unveil the role of VEGFR3 in thyroid capillaries, we generated
VEGFR3iΔEC mice by crossing the VEGFR3flox/flox mouse (Haiko et al,
2008) with the VE-Cadherin-Cre-ERT2 mouse (Fig 5A). Repeated
administrations of tamoxifen reduced the expression of VEGFR3 by
98%, but no changes in VEGFR2 expression were observed in the
ECs of thyroid vasculatures of VEGFR3iΔEC mice compared with those
of control mice (Fig 5B–F). However, no apparent differences in
gross features, vascular density, and numbers of apoptotic EC and
EC fenestrae were detected between the thyroid glands of control
and VEGFR3iΔEC (Fig 5G–L). Thus, the role of VEGFR2 is indispens-
able, but that of VEGFR3 is dispensable to maintain the integrity of
ECs of thyroid capillaries including endothelial fenestrae.
VEGF-A is required for maintenance of vasculature integrity and
PTU-induced angiofollicular remodeling in thyroid glands
We further evaluated the role of VEGF-A in adult normal thyroid
glands by using a VEGF-Trap (Holash et al, 2002), which has been
known to block VEGF-A, VEGF-B, and placental growth factor.
Compared with control, administration of VEGF-Trap (intraperi-
toneal injections of 25 mg/kg every 2 days for 2 weeks) reduced the
vascular density by 36%, regressed capillary beds, increased the
number of apoptotic ECs, but preserved NG2+ pericyte coverage
(Fig 6A–F), indicating that VEGF-A plays a substantial role in capil-
lary maintenance in adult thyroid glands. Furthermore, VEGF-Trap
reduced the number of fenestrae by 66%, whereas it increased the
number of caveolae by 242% (Fig 6G and H), indicating that the
capability of transcellular transport in thyroid ECs can also be seri-
ously impaired by VEGF-A blockade. Interestingly, fluorescence
image analyses indicated that the expression of VEGFR2 and
VEGFR3 was also decreased by 36 and 83%, respectively, in thyroid
capillaries after VEGF-Trap treatment (Fig 6I–L), noting that consti-
tutive stimulation of VEGFR2 in thyroid ECs by follicular VEGF-A is
required for the maintenance of thyroid vasculatures.
We next explored whether VEGF-A blockade affects PTU-induced
angiofollicular remodeling which mimics thyroid goiter. Starting
from day 7 after PTU administration by drinking water, the mice
received intraperitoneal injections of VEGF-Trap (25 mg/kg) every
2 days for the subsequent 2 weeks. Compared with control, admin-
istrations of PTU increased the vascular density by 53% and
◀ Figure 3. Expression of follicular cell-derived VEGF-A and endothelial VEGFR is altered by different circulating TSH level.A Images showing X-gal-stained VEGF-A in the thyroid glands of VEGF-A+/LacZ mice.
B–D Comparisons of VEGF-A mRNA and protein levels in thyroid glands, and circulating VEGF-A levels in serum.
E Phase contrast image of cultured rat thyroid follicular cell line, FRTL-5.
F Increases of VEGF-A mRNA expression in FRTL-5 cells at 3 h after TSH stimulation.
G Comparisons of VEGF-A mRNA levels in FRTL-5 cells after supplement with cell signal inhibitors. Cells were pretreated for 1 h with KT5720 (KT, 3 lM), Go6976 (Go,
0.1 lM), or LY294002 (LY, 20 lM) before TSH (1 mU/ml) supplementation.
H Images showing X-gal-stained VEGFR2 in the thyroid glands of VEGFR2+/LacZ mice.
I, J Immunofluorescence images showing expression of VEGFR2 and VEGFR3.
K Comparisons of VEGFR2 and VEGFR3 mRNA levels.
L Comparisons of expression of VEGFR2 and VEGFR3 (relative percentage to the levels of CD31) proteins.
Data information: Each group, n = 4 in (B, C, D, K, and L). Each group, n = 3 in (F and G). Error bars represent mean  s.d. Kruskal–Wallis test followed by Tukey’s
multiple comparison test was used in (B, C, D, F, K, and L). Mann–Whitney U-test was used in (G). ns, not significant. Scale bars, 50 lm.
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Figure 4. Inducible genetic deletion of VEGFR2 leads to vessel regression and loss of endothelial fenestrae in the thyroid gland.
A Diagram for EC-specific depletion of VEGFR2 in the thyroid vessels of 6-week-old VEGFR2iΔEC mice and their analyses 2 weeks later.
B–M Images and comparisons of (B–E) expression of VEGFR2 and VEGFR3 in CD31+ ECs, (F, G) CD31+ vascular density, (H, I) numbers of caspase-3+ apoptotic EC (white
arrows), (J, K) filopodia/sprouting (white arrows), and (L, M) fenestrae (black arrowheads) and caveolae (black arrows) in the thyroid capillaries of control
littermates (Co; n = 4–5) and VEGFR2iΔEC mice (VR2Δ; n = 4–5).
Data information: All scale bars, 50 lm except scale bars in (B), 500 lm, and scale bars in (L), 0.5 lm. Error bars represent mean  s.d. Mann–Whitney U-test was used
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vascular diameter by 161%, once again validating that PTU-induced
vascular remodeling leads to vascular enlargement in thyroid glands
(Appendix Fig S6A–D). However, VEGF-Trap treatment markedly
abrogated this PTU-induced effect, reducing the vascular density
and vascular diameter by 38 and 64%, respectively, almost comple-
tely restoring the thyroid vasculature to its normal state
(Appendix Fig S6A–D). Regardless of the predominant outcomes of
PTU-induced vascular remodeling, the vasculature of VEGF-Trap-
injected mice had well-organized morphology, even in high levels of
TSH, indicating that follicular VEGF-A is responsible for the
dynamic vascular remodeling by high TSH level. Strikingly, admin-
istration of VEGF-Trap markedly decreased the increased heights of
PTU-fed thyroid follicular cells by 64%, becoming very similar to
those of normal mice (Appendix Fig S6E and F). Furthermore, incre-
ments of the thyroid weights after PTU administration were strik-
ingly decreased by VEGF-Trap injection (Appendix Fig S6G and H).
Genetic depletion of VEGFR2 suppresses PTU-induced thyroid
angiofollicular remodeling and reduces goiter weights
To determine the role of VEGFR2 in the PTU-induced thyroid angio-
follicular remodeling, we administered PTU by drinking water for
3 weeks to ~6-week-old VEGFR2ΔiEC mice (Fig 7A). As control mice,
we used VE-Cadherin-Cre-ERT2 but flox/flox-negative mice among
the littermates for each experiment while PTU was administered for
3 weeks. Markedly reduced expression of VEGFR2 (84%) and
VEGFR3 (68%) was detected in the ECs of thyroid vasculatures of
VEGFR2ΔiEC mice by repeated administrations of tamoxifen
compared with those of control mice (Fig 7B–E). Strikingly, the
PTU-induced increases of thyroid vascular density, number of EC
fenestrae, heights of follicular cells, and thyroid weights were
reduced by 75, 82, 57, and 79%, respectively, in VEGFR2ΔiEC mice
compared with those of control mice (Fig 7F–M). Of note, EM
images revealed strikingly increased number of endothelial caveolae
by 1,444% and thickened cytoplasmic membrane of ECs in the
VEGFR2ΔiEC mice (Fig 7H and I). These findings demonstrate that
the PTU-induced vascular remodeling and goitrogenesis is mostly
dependent on VEGFR2 in the ECs of thyroid vasculatures. Long-term
depletion of VEGFR2 impairs the integrity of thyroid vasculatures.
VEGFR2 neutralizing antibody DC101 attenuates the PTU-induced
changes of angiofollicular remodeling, goiter weight, and
expression of TSH-responsive genes in thyroid glands
We further performed the experiment using DC101, a VEGFR2
neutralizing antibody, to see whether antibody-mediated VEGFR2
blockade can reduce the PTU-induced angiofollicular remodeling as
well as goiter weights. Starting from day 7 after PTU administration
by drinking water, the mice received intraperitoneal injections of
DC101 (25 mg/kg) every 2 days for the subsequent 2 weeks. In
comparison with Fc treatment, the vessel densities in the thyroids
were decreased by 43% after DC101 administration compared with
Fc-treated thyroids during PTU-induced goitrogenesis (Fig 8A and
E). Notably, we found that, compared with those of Fc treatment,
the heights of follicular cells were 65% less (Fig 8B and F), and the
thyroid weight was also reduced by 68% after DC101 administration
in PTU-fed mice (Fig 8C and G), both being restored very closely to
the levels of normal mice. Nevertheless, DC101 administration did
not significantly alter the elevated circulating TSH levels during the
PTU-induced goitrogenesis (Fig 8H). Compared with Fc administra-
tion, administration of DC101 for 2 weeks strikingly reduced the
endothelial fenestrae by 80% and increased endothelial caveolae by
298% in PTU-fed mice (Fig 8D, I and J). Consequently, we next
questioned whether the blockade of VEGFR2 would decrease the
expression levels of TSH-responsive genes in thyroid glands. Based
on previous reports (Gerard et al, 1988; Garcia & Santisteban, 2002;
Mascia et al, 2002), we selected three TSH-responsive genes, tran-
scription factor Pax8, thyroid peroxidase (TPO), and sodium/iodide
symporter (NIS), and performed quantitative real-time PCR analyses
in the thyroid glands after PTU with Fc or DC101 administration. As
expected, administration of PTU plus Fc significantly increased the
mRNA expression levels of Pax8 (~128-fold), TPO (~251-fold), and
NIS (~4,643-fold) in the thyroid glands compared with control mice
(Fig 8K). However, administration of PTU plus DC101 reduced the
mRNA level of TSH-responsive genes by 57% in Pax8, 43% in TPO,
and 55% in NIS compared with those of the PTU-fed thyroids
(Fig 8K). Thus, the reduction in thyroid EC fenestration by the
blockade of VEGFR2 ultimately diminished the TSH responsiveness
of follicular cells during PTU-induced goitrogenesis. Together, an
antibody-mediated blockade of VEGFR2 can abrogate vascular
remodeling as well as hypertrophy of follicular cells, leading to the
reduction of thyroid weight during PTU-induced goitrogenesis.
Microvessel density and VEGFR2 expression are increased in
thyroid glands of patients with Graves’ disease
The experimental model of PTU-induced thyroid goiter shares similar
features with human Graves’ disease, including thyrotropin receptor
hyper-stimulation and follicular hypertrophy. Thus, to validate
increases of VEGFR2 expression in human pathology, thyroid speci-
mens of Graves’ disease were examined in comparison with normal
thyroid glands as a control. Immunostaining of CD31 and VEGFR2
showed confined expression of VEGFR2 within CD31+ BVs, not
within follicular cells of normal or Graves’ disease-thyroids (Fig 9A
and B). CD31+ BV density was significantly increased in Graves’
disease-thyroid glands compared with control (Fig 9A and C). Impor-
tantly, the VEGFR2 immunostaining scores, measured as a sum of
signal intensity of immunoreactions and proportion of VEGFR2
expression on CD31+ BVs, were strikingly increased compared with
control (Fig 9B and D). Thus, microvessel densities and their VEGFR2
expression were increased in the patient with Graves’ disease.
Discussion
In this study, we found profound and distinct expression of VEGF-A,
VEGFR2, and VEGFR3, but no Ang1, Ang2, and Tie2, in thyroid glands.
Importantly, using genetically modified mice and selective blockades
of VEGF-A or VEGFR2, we uncovered the indispensable roles of VEGF-
A and VEGFR2 and dispensable role of VEGFR3 in the ECs of thyroid
capillaries for maintenance of integrity including endothelial fenestrae.
In addition, this study demonstrates that blockade of VEGFR2 mark-
edly ameliorates hypertrophy of follicular cells as well as vascular
remodeling, leading to amelioration of PTU-induced goitrogenesis.
Because inhibiting VEGF-A–VEGFR2 pathway affects not only its
main target of thyroid vasculatures but also neighboring follicular
ª 2017 The Authors EMBO Molecular Medicine
Jeon Yeob Jang et al Gatekeeping role of VEGFR2 in thyroids EMBO Molecular Medicine
11
Published online: April 24, 2017 
VEGFR2∆iEC 
P0 6w 7w 8w
Tamoxifen Analyses
9w
PTU administration
V
E
G
FR
2
/C
D
31
+
E
C
 (%
)
0
50
100
CoVR2∆
CB PTU (Control) PTU (VEGFR2i∆EC) 
V
E
G
FR
2 
 C
D
31
  
F
C
D
31
0
25
50
CoVR2∆
Va
sc
ul
ar
 d
en
si
ty
(%
)
G
0
50
100
CoVR2∆
V
E
G
FR
3
/C
D
31
+
E
C
 (%
)
E
V
E
G
FR
3 
 C
D
31
  D
M
N
o.
/1
0 
μm
 p
er
im
et
er
L
0
4
CoVR2∆
Th
yr
oi
d 
w
ei
gh
t (
m
g)
8
12
IH
0
30
60
90
Co
VR2∆
CaveolaeFenestrae
H
ei
gh
t o
f
th
yr
oc
yt
es
(μ
m
)J K
0
20
30
CoVR2∆
10
A
H
&E
E
le
ct
ro
n 
m
ic
ro
gr
ap
h
p=0.014
p=0.014
p=0.014
p=0.021
p=0.021
p=0.021
p=0.020
Figure 7. Inducible genetic deletion of VEGFR2 ameliorates thyroid angiofollicular remodeling during goitrogenesis.
A Diagram showing PTU administration into VEGFR2iΔEC mice.
B–K Images and comparisons of (B–E) expression of VEGFR2 and VEGFR3, (F, G) CD31+ BV density, (H, I) fenestrae (arrowheads) and caveolae (arrows), and (J, K) height
of thyrocytes in VEGFR2iΔEC (VR2Δ) and their littermate controls (Co) after 3 weeks of PTU administration. All scale bars, 50 lm except scale bars in (B), 500 lm, and
scale bars in (H), 0.5 lm.
L, M Gross images and comparisons of thyroid weights after 3 weeks of PTU administration in VEGFR2iΔEC mice compared with Co. Scale bar, 1 mm.
Data information: Each group, n = 4–5. Error bars represent mean  s.d. Mann–Whitney U-test was used in (C, E, G, I, K, and M).
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cells, we speculated that decreased transcellular permeability
through the inhibition of VEGF-A–VEGFR2 pathway may inhibit
TSH from reaching follicular cells. Consistently, blockade of
VEGFR2 was sufficient to result in loss of endothelial fenestrae with
decreases of TSH-responsive genes in thyroid glands, despite the
high circulating TSH levels during PTU-induced goitrogenesis. Thus,
thyroid VEGF-A–VEGFR2 pathway has a dual role, being responsible
for TSH-dependent vascular remodeling and maintenance of TSH
responsiveness of follicular cells by modulating endothelial fenes-
trae. Our findings highlight the importance of thyroid vasculature
that coordinates with its neighboring follicular cells to accomplish
proper hormonal feedback regulation.
We also delineated the phenotypic characterization and molec-
ular pathways that contribute to follicular and vascular remodel-
ing in thyroid glands under different circulating TSH level
conditions in mice. High level of TSH strongly stimulated thyroid
follicular cells through TSHR, and in turn the follicular cells
massively produced and secreted VEGF-A to activate VEGFR2 on
neighboring ECs in a paracrine manner. As a consequence, there
was not only profound vascular remodeling that was mainly char-
acterized by vascular enlargement, increased blood flow, and
increases of endothelial fenestrae, but also hypertrophy of follicu-
lar cells. Thus, thyroid vascular flow and permeability are finely
regulated to meet the endocrine requirements as regulated by TSH
stimulation.
Thyrotropin receptor hyper-activation has been known to be
associated with human thyroid diseases, such as Graves’ disease,
thyroid goiter, and tumor (Davies et al, 2005). Given that the stimu-
lation of thyrotropin receptor is the main mechanism of Graves’
disease, our PTU-induced mouse model of thyroid goiter shares
similar features with Graves’ disease, such as thyrotropin receptor
hyper-stimulation, hypertrophy of thyrocytes, and distinguishable
characteristics of vascular remodeling (Nagura et al, 2001; Davies
et al, 2005). Intriguingly, we found increased microvessel density
and their VEGFR2 expression in the thyroid glands of patient with
Graves’ disease. Moreover, administration of VEGFR2 blocking anti-
body, DC101, ameliorated PTU-induced follicular and vascular
remodeling and reduced thyroid weights nearly to the level of
normal mice. We suggest that these were achieved through
decreased transcellular transport capacities due to decreased vascu-
larity and endothelial fenestrations. It remains to be studied whether
decreased transcellular transport capacities through blockade of
VEGF-A or VEGFR2 will be able to reduce the contacts of circulating
IgG antibodies to follicular cells in Graves’ disease. Nevertheless,
inhibitors of VEGF-A–VEGFR2 signaling could reduce the sizes of
thyroid goiter, thus providing a novel therapeutic concept of
targeting vasculatures in these TSHR-associated diseases such as
Graves’ disease and warranting further clinical investigation.
Our findings indicate that, like other endocrine glands, thyroid
glands highly express VEGF-A, which is a critical molecule to sustain
the central thyroid function, release of thyroid hormones. This fact
may be an important clue for understanding the recent problems in
clinic regarding hypothyroidismal complications after anti-VEGF ther-
apy (Chan et al, 2007; van der Veldt et al, 2013; Cao, 2014).
Hypothyroidism was first reported in patients receiving sunitinib, a
small-molecule multiple tyrosine kinase inhibitor that also affects
VEGFRs (Desai et al, 2006; Rini et al, 2007). Moreover, another anti-
angiogenic agent, bevacizumab, has been reported to elicit reduced
thyroid perfusion with elevated TSH level (van der Veldt et al,
2013). Recently, a preclinical research comprehensively evaluated
the degree of vascular alterations in healthy mouse tissues in
response to VEGF-A and VEGFR2 blockades and reported that,
among all analyzed tissues and organs, the vasculatures of endocrine
organs were most heavily affected, particularly the thyroid (Kamba
et al, 2006; Yang et al, 2013; Zhang et al, 2016). Our analyses using
reporter mouse system might provide possible explanations for the
anti-VEGF therapy-induced hypothyroidism. Supporting these
reports, our results indicate that the decreases of endothelial fenes-
trae as well as vascular densities are one of the responsible causes of
thyroid dysfunction after anti-VEGF therapy. Nevertheless, several
blocking antibodies and small molecules for VEGF-A–VEGFR2 signal-
ing (Hurwitz et al, 2004; Van Cutsem et al, 2012; Wilke et al, 2014)
are currently being used for patients with solid cancers such as
colorectal cancers. Therefore, it would be ideal to follow up on the
progression of thyroid goiter for those who concurrently have cancer
and thyroid goiter and are being treated with such blocking agents.
One intriguing aspect of this study is the significant expression
and change of VEGFR3 in the ECs of quiescent and growing thyroid
vasculatures, similar to what was observed in growing retinal
vasculatures (Benedito et al, 2012). Considering the observed
expression patterns of VEGFR3 ligands (VEGF-A, high; VEGF-C,
low) in our study, and since it is already known that VEGFR2 and
VEGFR3 react with VEGF-A by forming a homodimer and hetero-
dimer with VEGFR2, respectively (Planas-Paz et al, 2012), we spec-
ulated that VEGFR3 might critically contribute to regulating the
number and shape of fenestrae in the endothelium of thyroid vascu-
lature. However, the analysis on the VEGFR3ΔiEC mice did not mean-
ingfully meet our speculation. Thus, VEGFR3 may play a
dispensable role, together with VEGFR2, in maintaining fenestration
of endothelium in the thyroid gland. These results appear to be
discrepant with a previous observation that genetic depletion of
endothelial VEGFR3 induces hypersprouting of growing retinal
▸Figure 8. Antibody-mediated VEGFR2 blockade ameliorates thyroid hypertrophy by reducing thyrotropin responsiveness during goitrogenesis.A, B Images showing CD31+ BVs and H&E-stained thyrocytes in mice treated with control (Co), PTU (for 3 weeks), PTU plus Fc (for 2 weeks), or PTU plus DC101 (DC, for
2 weeks). Scale bars, 50 lm.
C Gross images of thyroid glands. Scale bar, 1 mm.
D Transmission electron micrographs showing the interface between ECs and thyrocytes. Each indicated region (box) is magnified and shown as lower panel.
Arrowheads, endothelial fenestrae; arrows, endothelial caveolae. Scale bars, 0.5 lm.
E–J Comparisons of (E) CD31+ BV density, (F) height of thyrocytes, (G) thyroid weight, (H) serum TSH level, and (I, J) number of endothelial fenestrae and caveolae per
10 lm vessel perimeter in control mice (Co), or mice treated with PTU, PTU plus Fc (Fc), or PTU plus DC101 (DC). Each group, n = 4–7. Error bars represent
mean  s.d. Kruskal–Wallis test followed by Tukey’s multiple comparison test was used.
K Comparisons of relative mRNA levels of TSH-responsive genes including Pax8, TPO, and NIS in thyroid glands. Each group, n = 3–4. Error bars represent
mean  s.d. P < 0.05 versus Co. Kruskal–Wallis test followed by Tukey’s multiple comparison test was used.
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vessels (Tammela et al, 2011). While the previous study evaluated
growing retinal vessels during postnatal development, our model
system involved quiescent thyroid vasculatures during adulthood.
Thus, VEGFR3 may play an indispensable role in thyroid vascula-
ture during development period, which requires further evaluation.
Moreover, since TSHR can be expressed in vascular EC (Balzan
et al, 2012; Tian et al, 2014), TSH–TSHR signaling may also directly
regulate the expression or signaling of VEGFR2 and VEGFR3 in
thyroid vasculatures, which also needs to be further investigated.
In conclusion, we show that the vasculature of thyroid glands is
finely adapted in response to TSHR stimulation and that paracrine
VEGF-A–VEGFR2 pathway plays a pivotal role in maintaining tran-
scellular transport capacities through endothelial fenestrations,
thereby maintaining TSH responsiveness of follicular cells during
normal state and goitrogenesis. Our findings provide an integrated
view of vascular regulation in endocrine system and suggest
VEGFR2 blockade as a novel therapeutic avenue for targeting vascu-
latures in TSHR-associated thyroid goiter.
Materials and Methods
RT–PCR and quantitative real-time PCR analyses
Total RNA was extracted from the indicated tissues using RNeasy-
Plus Mini Kit (Qiagen) according to the manufacturer’s instructions.
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Figure 9. Microvessel density and VEGFR2 expression in human thyroid specimens of Graves’ disease.
A, B Images showing CD31+ BVs and VEGFR2 expression in normal and Graves’ disease-thyroids. Scale bars, 50 lm.
C, D Comparisons of number of CD31+ microvessels per high-magnification field (×400) and VEGFR2 immunostaining score in normal Graves’ disease-thyroids. Three
areas with the highest concentration of BVs were selected and evaluated in each sample. Error bars represent mean  s.d. Mann–Whitney U-test was used.
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The RNA (2 lg) was reverse-transcribed into cDNA using Super-
Script II Reverse Transcriptase (Invitrogen). Semi-quantitative RT–
PCR was performed using NobleZymeTM Taq (Noble Bio) with
the indicated primers. Quantitative real-time PCR (qPCR) was
performed with the indicated primers using Bio-RadTM CFX96 Real-
Time PCR Detection System (Bio-Rad). The real-time PCR data were
analyzed with Bio-Rad CFX Manager Software (Bio-Rad). Primers
for the semi-quantitative RT–PCR (Semi) and quantitative real-time
PCR analysis are indicated in Appendix Table S1.
Quantitative measurement for VEGF-A protein
On the indicated days, thyroid glands were harvested and homoge-
nized in ice-cold buffer containing a protease inhibitor cocktail.
Serums were obtained using a standard method. To evaluate the
secretory capacity of VEGF-A, an explant culture of mouse thyroid
gland was performed. Briefly, one lobe of thyroid gland in each
mouse was prepared by a gentle dissection and cultured in a 96-well
plate (SPL Life Sciences) containing 100 ll of 6H medium consisting
of Coon’s modified F-12 supplemented with 5% FBS. Concentrations
of VEGF-A protein in 10 lg of thyroid gland extract, 10 ll of serum,
and 50 ll of culture medium were measured using the mouse
VEGF-A ELISA kit (R&D systems) according to the manufacturer’s
protocol.
Mice
Animal care and experimental procedures were performed under
the approval from the Animal Care Committee of KAIST (KA2011-
21). All procedures and animal handlings were performed following
the ethical guidelines for animal studies. C57BL/6J and Tie2-GFP
(FVB/N) mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). Ang2-EGFP mouse was purchased from the Mutant
Mouse Regional Resource Centers. Ang1-GFP mouse (Zhou et al,
2015) was provided by Prof. Sean J. Morrison (University of Texas
Southwestern Medical Center, Dallas, USA). VEGF-A+/LacZ mouse
(Miquerol et al, 2000), VEGFR2+/LacZ mouse (Ema et al, 2006),
VEGF-C+/LacZ mouse (Karkkainen et al, 2004), VE-Cadherin-
Cre-ERT2 mouse (Okabe et al, 2014), VEGFR2flox/flox mouse
(Hooper et al, 2009), and VEGFR3flox/flox mouse (Haiko et al,
2008) were transferred and bred in specific pathogen-free animal
facilities at KAIST. VEGF-A+/LacZ mice (Miquerol et al, 2000) that
have elevated VEGF expression by 30UTR insertion of the IRES-
lacZ-pA sequence, resulting in increased stability of the VEGF-A
transcripts, were used in this study to examine the expression
patterns of VEGF-A since they showed almost similar vascular
structures and densities in the thyroid glands compared with
those of wild-type mice. The endothelial-specific VEGFR2 or
VEGFR3 knockout mouse line was generated by crossing the
VEGFR2flox/flox mouse or VEGFR3flox/flox mouse with VE-Cadherin-
Cre-ERT2 mouse. For all the experiments involving VEGFR2 or
VEGFR3 knockout mouse, the control mice were VE-Cadherin-Cre-
ERT2 but flox/flox-negative mice among the littermates for each
experiment. All mice used were males (6- to 8-week-old) and
maintained on a C57BL/6J strain background. The number of
mice used is indicated in each figure. The mice were assigned to
experimental groups based on their genotype. Tamoxifen (Sigma-
Aldrich) was dissolved in corn oil (Sigma-Aldrich) and
administered into the peritoneal cavity (2.0 mg per mouse) of the
indicated mice at the indicated time point. All mice were bred in
a temperature- and humidity-controlled specific pathogen-free
animal facility at KAIST, with a 12-h light/dark cycle, and fed
with ad libitum access to standard diet (PMI Lab diet) and water.
All mice were anesthetized by intramuscular injection of a combi-
nation of anesthetics (80 mg/kg of ketamine and 12 mg/kg of
xylazine) before being sacrificed.
Histological analysis
On the indicated days after the treatments, mice were anes-
thetized by an intramuscular injection of combined anesthetics.
Tissues including thyroid glands, trachea, and esophagus were
fixed in 1% paraformaldehyde, embedded with tissue freezing
medium (Leica) or paraffin, and sectioned. Samples were
blocked with 5% goat (or donkey) serum in PBST (0.1% Triton
X-100 in PBS) and incubated for 3 hr at room temperature (RT)
with the following primary antibodies: anti-CD31 (hamster, clone
2H8, Millipore), anti-NG2 (rabbit polyclonal, Millipore), anti-GFP
(rabbit polyclonal, Millipore), anti-VEGFR2 (rabbit, clone TO14,
gifted by Dr. Rolf A. Brekken), anti-VEGFR3 (goat polyclonal,
R&D Systems), anti-Ang2 (human monoclonal, clone 4H10; Han
et al, 2016), anti-PH3 (rabbit polyclonal, Millipore), anti-caspase-
3 (rabbit polyclonal, R&D Systems), and anti-GLUT1 (rabbit poly-
clonal, Millipore). After several washes with PBS, sections were
incubated for 2 h at room temperature with one or more of the
following secondary antibodies: Cy3- or FITC-conjugated anti-
hamster IgG (Jackson ImmunoResearch), Cy3- or FITC-conjugated
anti-rabbit IgG (Jackson ImmunoResearch), Cy3-conjugated anti-
rat IgG (Jackson ImmunoResearch), and Cy3- or FITC-conjugated
anti-goat IgG (Jackson ImmunoResearch). Nuclei were stained
with 40,6-diamidino-2-phenylindole (DAPI; Invitrogen). Zeiss LSM
510 confocal microscope equipped with argon and helium–neon
lasers (Carl Zeiss) was used to visualize the fluorescent signals
and to obtain digital images. Three-dimensional image recon-
struction of the confocal-acquired z-stack images was performed
using Imaris software (Bitplane AG, Zurich, Switzerland). This
software allowed the reconstruction of an isosurface for each flu-
orescent channel. To examine b-galactosidase activity, the cryo-
sections were incubated with a staining solution [2 mM magne-
sium chloride, 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide, and 1 mg/ml 4-chloro-5-bromo-3-indolyl-b-D-galac-
topyranoside (X-gal) in PBS] at 37°C for 1–12 h. Paraffin-
sectioned tissues were stained according to standard hematoxylin
and eosin (H&E) staining protocol. The H&E images were
captured by a microscope equipped with CCD camera (Carl
Zeiss). To detect hypoxic areas in thyroid glands, Hypoxyprobe-
1TM (60 mg/kg, solid pimonidazole hydrochloride, Natural Phar-
macia International) was intraperitoneally injected 60 min before
analyses. The thyroid glands were then harvested, sectioned, and
stained with FITC-conjugated anti-Hypoxyprobe antibody.
Preparations and treatments of reagents
The modulation of TSHR signaling in thyroid glands was achieved
by modulating the pituitary secretion of its ligand, TSH, through
the administration of T4 (Sigma) or PTU (Sigma) as previously
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described (Franco et al, 2011). In detail, to suppress the pituitary
secretion of TSH, T4 was dissolved in 4 M ammonium hydroxide
and administered to the mice via drinking water at an estimated
dose of 0.6 mg/kg/day. To increase the pituitary secretion of
TSH, PTU was dissolved in 2.8 M ammonium hydroxide and
administered to the mice via drinking water at an estimated dose
of 0.72 g/kg/day. All tested mice were sacrificed and examined at
indicated days. To produce recombinant proteins dimeric-Fc (Fc)
and VEGF-Trap, stable CHO cell lines that secrete these recombi-
nant proteins were used as previously described (Kim et al,
2013). A hybridoma cell line that expresses rat anti-VEGFR2 Ab,
DC101, was purchased from American Type Culture Collection
(ATCC). Hybridoma cells were grown in serum-free medium.
Recombinant proteins in the supernatants were purified by
column chromatography with Protein A agarose gel (Oncogene)
using acid elution. After purification, the recombinant proteins
were quantified using the Bradford assay and confirmed by
Coomassie blue staining after SDS–PAGE. Proteins were subcuta-
neously injected with the following dosages and schedules: VEGF-
Trap (25 mg/kg), DC101 (25 mg/kg), and Fc (25 mg/kg) every
2 days for 2 weeks.
Measurement of serum TSH
Peripheral blood was collected via tail vein by incision at the indi-
cated times. Blood was clotted for 30 min and centrifuged for
15 min at 3,300 g. Supernatant was collected and considered as
serum. The collected samples were stored at 80°C before analysis.
Serum TSH levels were measured by radioimmunoassay as previ-
ously described (Ying et al, 2005).
Intravital imaging
Intravital imaging for thyroid gland vasculature was performed
with the confocal imaging platform using a homebuilt micro-
scope as previously described (Kim et al, 2008). Briefly, mice
were anesthetized by intramuscular injection of combined anes-
thetics and surgical procedures were performed to expose thyroid
glands followed by intravital imaging. To visualize blood vessels
(BVs), 100 ll of FITC-conjugated dextran (5 mg/ml, 200 MDa,
Sigma) was injected intravenously. To evaluate the blood flow
in the thyroid glands, fluorescence-labeled RBCs using Vybrant
DiD Cell-Labeling Solution (Invitrogen) was adoptively trans-
ferred 10 min before intravital imaging. The confocal system
involves two continuous-wave laser emitting at 488 nm (OBIS,
Coherent) and 640 nm (Cube, Coherent) as excitation sources.
The field of view (FOV) was 250 × 250 lm at the focal plane of
a 40× objective lens (LUCPlanFL, numerical aperture (NA) = 0.6,
Olympus). Images were displayed as 512 × 512 pixels per frame
at a frame rate of 30 Hz and stored in a hard disk in real time
by using a custom-written software and Matrox Imaging Library
(MIL9).
Transmission electron microscopy
Tissues of the thyroid glands were fixed with 2.5% glutaraldehyde
(Ted Pella) in PBS overnight and washed five times with cacodylate
buffer (0.1 M) containing 0.1% CaCl2. Tissues were post-fixed for
2 h with 1% OsO4 in 0.1 M cacodylate buffer (pH 7.2) and washed
in cold distilled water. Tissue dehydration was conducted with
ethanol series and propylene oxide, and the tissues were embedded
in Embed-812 (EMS). Following resin polymerization for 36 h, the
tissues were serially sectioned using an ULTRACUT UC7 ultramicro-
tome (Leica, Austria) and mounted on Formvar-coated slot grid.
After staining with 4% uranyl acetate and lead citrate, the sections
were observed using a Tecnai G2 Spirit Twin transmission electron
microscope (FEI).
Morphometric analysis
Morphometric analyses of thyroid glands were performed using
ImageJ software (http://rsb.info.nih.gov/ij) or LSM Image Browser
(Carl Zeiss). Heights of thyrocytes were averaged among 10 consec-
utive thyrocytes in H&E-stained images. For vascular densities,
CD31+ area was measured in 0.2-mm2 areas and presented as a
percentage of the total measured area. Vascular diameters were
averaged among 10 consecutive FITC–dextran-perfused blood
vessels in three random 0.05-mm2 areas. Numbers of PH3+/CD31+
ECs or caspase-3+/CD31+ ECs were measured in three random
0.05-mm2 areas. Numbers of fenestrae and caveolae in 10 lm vessel
perimeter of the capillary ECs were measured on 5–8 random areas
of TEM images (Kamba et al, 2006). Coverage of NG2+ pericytes to
BVs was calculated as NG2+ area divided by CD31+ BV area in
three random 0.05-mm2 areas of each thyroid gland and presented
as a percentage. Expression of VEGFR2 and VEGFR3 was deter-
mined by measuring the signal densities in three random 0.053-
mm2 areas and presented as a relative percentage to the signal
densities of CD31.
Reagents, cells, and culture condition for in vitro studies
FRTL-5 cell line was purchased from American Type Culture
Collection (ATCC). The cells were grown in 6H medium consist-
ing of Coon’s modified F-12 (Sigma) supplemented with 5% fetal
bovine serum (Gibco), 1 mM nonessential amino acids (Gibco),
and a mixture of six hormones as follows: bovine TSH (1 mU/
ml, Sigma), bovine insulin (10 lg/ml, Sigma), hydrocortisone
(0.4 ng/ml, Calbiochem), human transferrin (5 lg/ml, Sigma),
glycyl-L-histidyl-L-lysine acetate (10 ng/ml, Sigma), and somato-
statin (10 ng/ml, Sigma). Media were changed every 2–3 days,
and cells were passaged every 7–10 days. In each experiment,
the cells were incubated in 4H medium (which is devoid of
insulin and TSH) with 0.2% FBS for 2 days and were treated
with indicated doses of TSH for 3 h. To block each specific
signaling pathway, the cells were pretreated with 3 lM KT5720
(protein kinase A inhibitor, Calbiochem), 0.1 lM Go6976
(protein kinase C inhibitor, Calbiochem), or 20 lM LY294002
(PI3K inhibitor, Calbiochem) in 0.1% DMSO-containing media
1 h prior to adding TSH (1 mU/ml). The cells cultured in 0.1%
DMSO media without additional inhibitors were used as a
control.
Patients’ data
Experimental procedures with human pathologic specimens were
approved by the Institutional Review Board of Pusan National
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University Hospital (PNUHIRB-017). All human samples were
collected by the tissue bank of Pusan National University Hospital,
Busan, Korea, with the informed consents from the donors follow-
ing the bioethics and safety regulations. The diagnoses of the spec-
imens included Graves’ diseases (n = 4) and papillary thyroid
cancer (n = 5) for evaluation of normal contralateral lobe of the
thyroid gland. The formalin-fixed, paraffin-embedded sectioned
tissues were used to examine BV density and VEGFR2 expression.
Immunostaining was carried out using the Bond-Max autostainer
and reagents (Vision Biosystems). Deparaffinization was done
automatically in the autostainer with Bond Wash solutions for
30 min. The slides were then incubated with Epitope Retrieval
Solution 1 (Leica Biosystems, Wetzlar, Germany) for 20 min,
peroxide block for 5 min, primary monoclonal antibody for
15 min, post-primary reagent for 8 min, and polymer for 8 min.
Anti-VEGFR2 (55B11, Cell Signaling Technology) and anti-CD31
(JC70A, DAKO) were used as the primary antibodies. To measure
number of CD31+ microvessels in thyroid glands, three areas with
the highest concentration of BVs were selected after scanning at
low-power field (40×). Then, each area was evaluated with high-
power field (400×) and the average number of microvessels per
high-power field was determined. VEGFR2 immunostaining score
was measured by a pathologist according to a semi-quantitative
manner as a sum of the intensity (score, 0–3) and proportion
(score, 0–3) of immunoreactions. Proportion was scored for the
percentage of CD31+ BVs (0, 0; 1, < 5%; 2, 5–50%; 3, > 50%).
Statistical analysis
Sample sizes were estimated by a power analysis (“TrialSize” pack-
age of R3.2.3 version) to detect a 20–40% difference (d) with a
significance level (a) of 0.05 and power (b) of 0.8. Animals or
samples were not randomized during experiments and not excluded
from analyses. The investigators were not blinded to group alloca-
tion during experiments and outcome analyses. Values are
presented as mean  standard deviation (s.d.). Significant dif-
ferences between the groups were determined by two-sided Mann–
Whitney U-test between two groups. In case of multiple groups,
significant differences between the groups were determined by
Kruskal–Wallis test with Tukey’s multiple comparison test. Statisti-
cal analysis was performed using PASW Statistics 18 (SPSS). Statisti-
cal significance was set at P < 0.05.
Expanded View for this article is available online.
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